Exchange: NASDAQ·Updated 04:02 AM EDT
DBVT logo

DBVTDBV Technologies

$14.33
$0.24
(1.65%)
Pre-Market
Prev Close $14.57
Reported EarningsJul 16
Mkt Cap$862.3M
Vol32.00

About

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
125

Frequently Asked Questions

What is Market Cap of DBV Technologies - ADR?
What is the 52-week high for DBV Technologies - ADR?
What is the 52-week low for DBV Technologies - ADR?
What is DBV Technologies - ADR stock price today?
What was DBV Technologies - ADR stock price yesterday?
What is the PE ratio of DBV Technologies - ADR?
What is the Price-to-Book ratio of DBV Technologies - ADR?
What is the 50-day moving average of DBV Technologies - ADR?
How many employees does DBV Technologies - ADR have?